Physician profile
John M Fleming
NPI 1093744807
$1,108.27
in general payments reported to CMS, 2019-2025
20 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $283 · 2021: $135 · 2022: $202 · 2023: $115 · 2024: $141 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $363 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $363.12 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $264.46 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.55 | 2020-2024 | Andexxa |
| Organogenesis INC. | $98.64 | 2021-2025 | Puraply Wound Matrix |
| Abbvie INC. | $91.24 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $72.67 | 2022 | |
| Csl Behring | $67.14 | 2023-2024 | Kcentra |
| E.R. Squibb & Sons, L.L.C. | $53.73 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $44.23 | 2020 | |
| Rare Disease Therapeutics, INC. | $43.50 | 2019-2024 | Anavip |
| Allergan, INC. | $41.07 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $39.92 | 2019 | |
| Pfizer INC. | $35.29 | 2020-2025 | |
| Abbott Laboratories | $23.99 | 2021 | |
| Brainscope Company, INC. | $21.45 | 2023 | Brainscope One |
| Smith+Nephew, INC. | $19.13 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioxcel Therapeutics, INC. | $18.20 | 2023 | Igalmi |
| Gilead Sciences, INC. | $16.84 | 2025 | |
| Eagle Pharmaceuticals, INC. | $16.08 | 2023 | |
| Ultragenyx Pharmaceutical INC. | $15.28 | 2023 | |
| Genentech USA, INC. | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.